Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057862 · ClinicalTrials.gov registry record · Phase 2
Investigation of Naltrexone for Pathological Gambling
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01057862 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 9 participants.
The verdict
NCT01057862, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as usual.
Interventions
- OTHER Placebo
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-02 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057862
The ClinicalTrials.gov registry entry for NCT01057862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01057862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057862 about?
NCT01057862 is a clinical study titled "Investigation of Naltrexone for Pathological Gambling". The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as ...
What is the current status of trial NCT01057862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-02. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01057862?
The interventions under investigation include: Placebo (OTHER), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01057862?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.